医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Celltrion Signs ‘Incubation’ Agreement with Emory University for Development of New Drugs for Atherosclerosis

2018年09月20日 AM11:03
このエントリーをはてなブックマークに追加


 

INCHEON, South Korea

Celltrion, Inc. (KRX:068270) signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis.

‘Incubation’ agreement is one of the open innovation measures by which a company provides its internal resources and capabilities, such as research space and facility, manpower and business operation consulting, to an external research institute or startup so as to support the research and ensure autonomy of the research aimed at developing new drugs or next-generation technology on the condition that the company can preferentially discuss commercialization of the research output.

Under the agreement, Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidates for atherosclerosis. Celltrion will have a preferential right to acquire a license for inventions resulting from the agreement.

Atherosclerosis is a vascular disease, in which the blood vessels are narrowed or clogged due to plaque made up of fat, cholesterol, immune cells and vascular wall cells in the blood vessel. This results in ischemic heart diseases (e.g., myocardial infarction and angina), stroke and peripheral arterial disease. Ischemic heart disease and stroke are the world’s leading causes of death, accounting for a combined 15.2 million deaths worldwide in 2016.1

Statins2 that lower cholesterol and lipid levels in blood are widely used to alleviate the onset and progression of atherosclerosis. Despite the success of lipid lowering drugs, atherosclerotic diseases continue to be the major cause of death worldwide. This highlights the need to develop new drugs that can complement the lipid lowering drugs by targeting new mechanisms of action to prevent and reduce the risk of atherosclerotic diseases.

“We are delighted to cooperate with the internationally renowned research team at Emory University led by Dr. Hanjoong Jo, John and Jan Portman Endowed Professor and Associate Chair in the Department of Biomedical Engineering and the Division of Cardiology, who is a leader in the area of mechanically regulated genes in atherosclerosis research,” says the official of Celltrion. “Based on this Incubation agreement, Celltrion will make further plans to secure more various new drugs and technologies. We are hoping that more research institutes and corporations will take an interest in our open innovation.”

Meanwhile, Celltrion recently announced a plan of launching Bio CDMO (Contract Development and Manufacturing Organization) business, in a bid to pursue open innovation for development of new drugs.

1 WHO. The top 10 causes of death. 2018-05-24
2 Cholesterol synthesis inhibitor; the drugs are said to be taken daily by over 30 million people worldwide for the treatment of high blood cholesterol.

About Celltrion, Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for INFLECTRA® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. For more information, visit www.celltrion.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180919005898/en/

CONTACT

Celltrion, Inc.
Gunn Lee, +82 32 850 5168
Gunhyuk.lee@celltrion.com
or
Heewon
Park, +82 32 850 5356
Heewon.park@celltrion.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • シアトル・ジェネティクスと武田薬品がCD30発現末梢性T細胞リンパ腫のフロントライン治療でアドセトリス(ブレンツキシマブ・ベドチン)を検討する第3相ECHELON-2臨床試験の良好なデータを発表
  • Seattle Genetics和武田呈报 ADCETRIS® (Brentuximab Vedotin)用于表达CD30的外周T细胞淋巴瘤一线治疗3期ECHELON-2临床试验的阳性数据
  • Brii Biosciences Builds Innovative Pipeline, Forges Public-Private Partnerships to Bring Novel Medicines to Chinese Patients
  • 从SmartZyme BioPharma剥离的公司Carnot BioSciences与Hemoshear Therapeutics合作开发用于罕见代谢性疾病的蛋白质类治疗药物
  • 武田薬品、プロテアソーム阻害剤による維持療法を評価する初のピボタル第3相プラセボ対照試験TOURMALINE-MM3の良好データを発表へ